SCOPE Summit 2025: Jonathan Norman of YPrime Discusses the Need for Localization in Clinical Trials
In an interview with ACT senior editor Andy Studna at SCOPE Summit, Norman, director, localization services, YPrime discussed how localization is becoming increasingly important as clinical trials become more global.
ACT: With sponsors increasingly conducting global studies, how does effective localization of eCOA instruments contribute to accelerating trial launches and overall study timelines?
Norman: As trials go more and more global, it's really important that we consider the impact that that has on the needs for localization. If you're speaking to more patients in more places, then obviously you need to have more languages available to be able to communicate and collect the data from those from those patients. As we are considering those bigger scopes, it is really important that we are looking for efficiencies in the localization process so that we are able to do this in a way that doesn't impact the trial timelines for those sponsors overall. The other element to really keep in mind is that identifying these countries early in the process, or these other populations in the process is really important so the relevant providers have the time that they need to create those translations in an effective way that's going to ensure the integrity of your data, so that they're able to do that in advance or deal with that as part of the study startup timelines without impacting the trial and causing delays later on.
SCOPE Summit 2025 Opening Keynote Panel: What Do Real Patients Actually Talk About?
February 3rd 2025Interactive panel on day 1 of SCOPE Summit 2025 highlighted the need for inclusive narratives, social listening to understand patient experiences, and the role of advocacy groups in opening doors to clinical trials.
